North East and North Cumbria
ICS Formulary
ICS Formulary
5 Infections
05-03-02-02 Cytomegalovirus infection
| Letermovir Prevymis® |
|
Formulary
|
|
 NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
|
| Maribavir Livtencity® |
|
Formulary
|
|
|
NICE TA860: Maribavir for treating refractory cytomegalovirus infection after transplant |
|
unlicensed)Links
- COVID-19 Therapeutic Alert
- Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients (Version 5 - effective from 10th February 2022)
NENC ICB - Cellulitis Diagnosis and Management in Ambulatory Adults in primary care; Supporting Information- NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
- NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population
- NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
- NICE TA860: Maribavir for treating refractory cytomegalovirus infection after transplant
- North of Tyne, Gateshead and North Cumbria - Antibiotic and Diagnostic quick reference tools
- Primary Care Antimicrobial Guidelines
- TEWV: Antibiotic Prescribing Procedure
- UK Interim Clinical Commissioning Police - Therapies for patients with symptomatic hospital-onset COVID-19